Retrovirology

Table 2 Neutralisation of early patient viruses by sequential autologous plasma

From: Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection

Patient	MM24
DFOS	44	93	124	208	292	409	464	555	834
IC90	< 10	< 10	< 10	80	320	640	640	640	640
IC50	10	10	10	320	1280	1280	1280	2560	1280
Patient	MM25
DFOS	31	38	66	94	185
IC90	< 10	< 10	< 10	< 10	10
IC50	< 10	< 10	< 10	< 10	40
Patient	MM26
DFOS	55	76	83	111	139	169	253	337	474
IC90	< 10	< 10	< 10	< 10	< 10	< 10	10	40	80
IC50	< 10	< 10	< 10	< 10	< 10	10	40	160	320
Patient	MM27
DFOS	46	53	109	299	585	755
IC90	< 10	< 10	< 10	< 10	< 10	< 10
IC50	< 10	< 10	< 10	< 10	< 10	< 10
Patient	MM28
DFOS	20	34	62	93	198	405	503	782	950
IC90	< 10	< 10	< 10	< 10	< 10	< 10	< 10	< 10	< 10
IC50	< 10	< 10	< 10	< 10	< 10	< 10	< 10	< 10	20
Patient	MM32
DFOS	10	14	21
IC90	< 10	< 10	< 10
IC50	< 10	< 10	< 10
Patient	MM33
DFOS	26	33	69	96	201	523	621	719
IC90	< 10	< 10	< 10	< 10	< 10	< 10	< 10	< 10
IC50	< 10	< 10	< 10	< 10	< 10	< 10	< 10	< 10
Patient	MM34
DFOS	32	45	74	192	443	607	759
IC90	< 10	< 10	< 10	< 10	< 10	< 10	10
IC50	< 10	< 10	< 10	< 10	< 10	< 10	10
Patient	MM38
DFOS	29	36	51	58	93
IC90	< 10	< 10	< 10	< 10	< 10
IC50	< 10	< 10	< 10	< 10	< 10
Patient	MM42
DFOS	22	29	36	43	57	92	183	238	324
IC90	< 10	< 10	< 10	< 10	< 10	< 10	< 10	< 10	< 10
IC50	< 10	< 10	< 10	< 10	< 10	< 10	< 10	< 10	< 10

Early patient viruses (detailed in Table 1) and sequential autologous plasma samples were analysed by standard TZMbl neutralisation assay. Plasma time points are represented by DFOS (days following onset of symptoms) as for serum samples used throughout this study. IC50 and IC90 values represent the highest plasma dilution at which reductions in infection of 50 and 90%, respectively, are achieved relative to control cultures.

Back to article page

ISSN: 1742-4690

Contact us

Submission enquiries: journalsubmissions@springernature.com